Overview

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the efficacy of DMF in Chinese participants with RMS at Week 48. The secondary objectives of the study are to assess the efficacy and safety of DMF in Chinese participants with RMS.
Phase:
Phase 4
Details
Lead Sponsor:
Biogen
Treatments:
Dimethyl Fumarate